This company is no longer active
ZSAN.Q Stock Overview
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Zosano Pharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0007 |
| 52 Week High | US$24.80 |
| 52 Week Low | US$0.0001 |
| Beta | 2.73 |
| 1 Month Change | 133.33% |
| 3 Month Change | -99.45% |
| 1 Year Change | -100.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Can Zosano Pharma (NASDAQ:ZSAN) Afford To Invest In Growth?
Nov 02
Is Zosano Pharma (NASDAQ:ZSAN) Weighed On By Its Debt Load?
Jun 29Shareholder Returns
| ZSAN.Q | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 40.0% | 1.5% | 2.9% |
| 1Y | -100.0% | 9.9% | 11.9% |
Return vs Industry: ZSAN.Q underperformed the US Medical Equipment industry which returned -22.2% over the past year.
Return vs Market: ZSAN.Q underperformed the US Market which returned -20.2% over the past year.
Price Volatility
| ZSAN.Q volatility | |
|---|---|
| ZSAN.Q Average Weekly Movement | 4,827.6% |
| Medical Equipment Industry Average Movement | 9.5% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.2% |
Stable Share Price: ZSAN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: ZSAN.Q's weekly volatility has increased from 2395% to 4789% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 40 | Steven Lo | www.zosanopharma.com |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma Corporation Fundamentals Summary
| ZSAN.Q fundamental statistics | |
|---|---|
| Market cap | US$3.43k |
| Earnings (TTM) | -US$55.19m |
| Revenue (TTM) | US$659.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs ZSAN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZSAN.Q income statement (TTM) | |
|---|---|
| Revenue | US$659.00k |
| Cost of Revenue | US$20.85m |
| Gross Profit | -US$20.19m |
| Other Expenses | US$35.01m |
| Earnings | -US$55.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.26 |
| Gross Margin | -3,063.13% |
| Net Profit Margin | -8,375.11% |
| Debt/Equity Ratio | 0% |
How did ZSAN.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/27 01:57 |
| End of Day Share Price | 2022/11/25 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zosano Pharma Corporation is covered by 7 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |